Faber Daeufer & Itrato – Drug, Life Sciences, and Technology Law Firm

When we look at a term sheet, we see a single piece of an overall business strategy.

Our goal is to design a transaction, not just to monetize IP, but also to drive the growth of your entire business. We can help you in the following ways:

Start-up

License core technologies and obtain venture financing

Learn More

clinical study

Launch and complete a complex clinical trial

Learn More

partner

Structure a research or product development collaboration

Learn More

exit

Close a strategic transaction for growth or exit

Learn More

Start-up

License core technologies and obtain venture financing

Learn More

clinical study

Launch and complete a complex clinical trial

Learn More

partner

Structure a research or product development collaboration

Learn More

exit

Close a strategic transaction for growth or exit

Learn More

ReveraGen BioPharma Inc.-Santhera Pharmaceuticals (Switzerland) Ltd— Idorsia Pharmaceuticals Ltd

Assignment, Amendment and Early Option Exercise Agreements

Assignment by Idorsia to Santhera of Idorsia’s option to license ReveraGen’s treatment for DMD in Phase III, and simultaneous amendment of the option agreement to provide for early exercise of Santhera’s option under revised terms

Press Release

Ipsen Bioscience Inc. - Université de Montréal

Research and Option Agreement to Acquire Exclusive License

Faber assisted Ipsen with a Research and Option Agreement under which Université de Montréal would conduct a lead optimization program on a high-value oncology program. Upon exercise of the option at the end of the research term, Ipsen would acquire an exclusive license for the worldwide rights to the program.

Press Release

DermBiont, Inc.

Series A Financing

$8 million Series A financing led by Viking Global Investors, Toba Capital and Zola Global Investors

Press Release

Blue Oak Pharmaceuticals, Inc.

Equity Securities

Equity Securities financing led by Viva Incubator Investment Management Limited and ShangPharma Investment Group

Website

Ipsen Bioscience Inc.— Blueprint Medicines Corp.

Exclusive License Agreement

Exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP) (including up to $535 million in potential development, regulatory and sales-based milestones and other payments, plus tiered percentage royalties)

Press Release

Lundbeckfond Ventures—New Enterprise Associates 14, LP

Royalty Sale

Lundbeckfond’s sale to New Enterprise Associates 14, LP of certain royalty rights receivable in connection with the merger of Vtesse Inc. with and into a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.

Website

FOG Pharmaceuticals, Inc.

Series B Financing

FogPharma raises $66,000,000 of Series B Financing, led by 6 Dimensions Capital L.P., with participation by GV, Blue Pool Capital, Horizons Ventures, Nan Fung Group, Leerink Partners and all existing Series A investors

Press Release

Alnylam Pharmaceuticals, Inc.—Vir Biotechnology, Inc.

Collaboration and License Agreement

Exclusive license with Vir Biotechnology to develop and commercialize RNAi therapeutics for chronic hepatitis B virus (HBV) infection and a research collaboration for other infectious diseases

Sojournix, Inc.

Series C Financing

Sojournix, Inc. raises Series C equity funding from RA Capital Management, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock Healthcare Capital Partners and Janus Henderson Investors

Press Release